This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of Ivonescimab (SMT112 or AK112) or Placebo Plus Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Quebec
Montreal
|
ClinicalTrials.gov Identifier:
|
NCT03769103
|
This study is currently recruiting participants.
This open-label, multicenter, randomized phase II study will evaluate the usage of osimertinib alone for brain metastases compared to SRS and osimertinib in patients with newly diagnosed, treatment naiive EGFR positive lung cancer.
British Columbia
BC Cancer, Vancouver Centre, Vancouver
Contact: Shilo Lefresne, MD 604 877 6000 ext 2673
[email protected]
Contact: Cheryl Ho, MD 604 877 6000 ext 2445
[email protected]
Ontario
Princess Margaret Hospital, Toronto
Contact: Adrian Sacher
Contact: David Shultz
Sunnybrook Health Sciences Centre, Toronto
Contact: Mark Doherty
Contact: Arjun Sahgal
| ClinicalTrials.gov Identifier: |
NCT04931654 |
This study is currently active and recruiting participants
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib
Alberta
Calgary
Edmonton
Ontario
Newmarket
North York
Toronto
| ClinicalTrials.gov Identifier: |
NCT05364073 |
This study is currently active and recruiting participants
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).
Alberta
Edmonton
Ontario
Toronto
| ClinicalTrials.gov Identifier: |
NCT04335292 |
This study is currently recruiting participants.
This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line treatment with osimertinib and second-line treatment with platinum and pemetrexed chemotherapy. The current standard of care for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung Cancer (aNSCLC) is osimertinib, followed by cytotoxic chemotherapy.
The repeat of osimertinib following previous treatment failure is investigational, although supported by scientific rationale. The dosing and scheduling of osimertinib follows its use in approved settings. The investigators examine its tolerability and efficacy in this setting to ensure osimertinib is a safe third-line option for patients with Epidermal Growth Factor Receptor mutated (EGFR+) Advanced Non-Small Cell Lung Cancer(aNSCLC).
British Colombia
Vancouver
Ontario
Brampton
Hamilton
Kitchener
London
Oshawa
Ottawa
Toronto
| ClinicalTrials.gov Identifier: |
NCT05261399 |
This study is currently recruiting participants.
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Ontario
Toronto
Quebec
Montreal
| ClinicalTrials.gov Identifier: |
NCT04862780 |
This study is currently recruiting participants.
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib.
Ontario
Princess Margaret Cancer Centre, Toronto
|
ClinicalTrials.gov Identifier:
|
NCT04035486
|
This study is active but not recruiting participants.
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer.
Alberta
Calgary
Edmonton
Ontario
Toronto
Quebec
Montreal
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
| ClinicalTrials.gov Identifier: |
NCT03333343 |
This study is currently active but not recruiting participants.
The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced EGFR-mutant NSCLC.
Ontario
Toronto
| ClinicalTrials.gov Identifier: |
NCT03318939 |
This study is active but not recruiting participants
This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-naïve NSCLC patients.
Alberta
Cross Cancer Institute, Edmonton
Ontario
London Regional Cancer Program, London
Princess Margaret Hospital, Toronto
British Columbia
BC Cancer, Vancouver
| ClinicalTrials.gov Identifier: |
NCT05388669 |
This study is active, but not recruiting participants.
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
Ontario
The Ottawa Hospital Cancer Centre, Ottawa
Princess Margaret Hospital, Toronto
| ClinicalTrials.gov Identifier: |
NCT02609776 |
This study is active, but not recruiting participants
The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).
British Columbia
Vancouver
Ontario
University Health Network, Toronto
| ClinicalTrials.gov Identifier: |
NCT02503722 |
This study is currently active but not recruiting participants
This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after treatment with an EGFR tyrosine kinase inhibitor. Sapanisertib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
| British Columbia |
| BCCA-Vancouver Cancer Centre |
|
| Vancouver, British Columbia, Canada, V5Z 4E6 |
| Contact: Site Public Contact, 888-939-3333 |
Principal Investigator: Cheryl Ho
|
| Ontario |
| University Health Network-Princess Margaret Hospital |
|
| Toronto, Ontario, Canada, M5G 2M9 |
| Contact: Site Public Contact, 416-946-4501 [email protected] |
| Principal Investigator: Penelope A. Bradbury |
| ClinicalTrials.gov Identifier: |
NCT02414139 |
This study is currently active but not recruiting participants
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC).
Ontario
Novartis Investigative Site
Ottawa, Ontario, K1H 8L6
| ClinicalTrials.gov Identifier: |
NCT0538869 |
This study is active, but not recruiting participants.
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
Ontario
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada, K1H 8L6
Princess Margaret Hospital, Toronto, Ontario, Canada, M5G 1Z5
| ClinicalTrials.gov Identifier: |
NCT02609776 |
This study is active, but not recruiting participants
The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).
British Columbia
Vancouver
Ontario
University Health Network, Toronto
|
ClinicalTrials.gov Identifier
|
NCT02414139
|
This study is active but not currently recruiting participants
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
Nova Scotia
Halifax
Ontario
Ottawa
|
ClinicalTrials.gov Identifier:
|
NCT04487080
|
This study is active but not recruiting participants.
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Ontario
Ottawa Hospital, Ottawa
Sunnybrook Cancer Centre, Toronto
Juravinski Cancer Centre, Hamilton
Quebec
McGill University Hospital, Montreal
EGFR Exon 20
|
ClinicalTrials.gov Identifier:
|
NCT05241893
|
This study is currently recruiting participants.
This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day treatment cycle.
Ontario
Princess Margaret Cancer Centre
| ClinicalTrials.gov Identifier: |
NCT05668988 |
This study is currently recruiting participants.
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage.
Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without).
Ontario
University Health Network, Toronto
|
ClinicalTrials.gov Identifier:
|
NCT04129502
|
This study is active but not currently recruiting.
The purpose of this study is to compare the efficacy of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
British Columbia
BC Cancer Agency, Vancouver
Alberta
Tom Baker Cancer Centre, Calgary
Ontario
William Osler Health System, Brampton
Princess Margaret Hospital, Toronto
Quebec
Hopital du Sacre Coeur de Montreal, Montreal
|
ClinicalTrials.gov Identifier:
|
NCT04538664
|
This study is active but not currently recruiting.
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.
Alberta
Edmonton
Ontario
Ottawa Hospital, Ottawa
Sunnybrook Cancer Centre, Toronto
Quebec
McGill Universtiy Health Centre, Montreal
| ClinicalTrials.gov Identifier: |
NCT05712902 |
This study is active but not recruiting participants
This is a Phase II, single-arm, multi-center clinical study to evaluate the anti-tumor efficacy, safety, tolerability and pharmacokinetics of DZD9008 in participants with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed on prior platinum-based chemotherapy
Ontario
Princess Margaret Cancer Centre
HER2
|
ClinicalTrials.gov Identifier:
|
NCT05048797
|
This study is currently recruiting participants.
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
British Columbia
Vancouver
Ontario
Brampton
Toronto
Quebec
Montreal
| ClinicalTrials.gov Identifier: |
NCT04727151 |
This study is currently active and recruiting participants
TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T cell receptor.
This is an open-label, multicenter Phase 1/2 study that aims to establish safety, Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 in subjects with relapsed or refractory solid tumors.
Ontario
Princes Margaret Hospital, Toronto
| ClinicalTrials.gov Identifier: |
NCT05364073 |
This study is currently active and recruiting participants
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).
Alberta
Edmonton
Ontario
Toronto
KRAS
A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRASG12C Mutant Advanced Solid Tumors (MK-1084-001)
|
ClinicalTrials.gov Identifier:
|
NCT05067283
|
This study is currently recruiting participants.
This is a study evaluating the efficacy, safety, and pharmacokinetics of MK-1084 in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.
Ontario
Hamilton Health Sciences, Juravinski Cancer Centre
Princess Margaret Cancer Centre, Toronto
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
|
ClinicalTrials.gov Identifier:
|
NCT04919811
|
This study is currently recruiting participants.
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years
Alberta
Cross Cancer Institute, Edmonton
Contact 855-569-6305
Ontario
Princess Margaret Hospital, Toronto
Contact 855-569-6305
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170)
|
ClinicalTrials.gov Identifier:
|
NCT05789032
|
This study is currently recruiting participants.
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Ontario
Toronto, Princess Margaret Cancer Center
Quebec
Montreal, Jewish General Hospital
|
ClinicalTrials.gov Identifier:
|
NCT04185883
|
This study is currently recruiting participants.
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors
Quebec
Laval
|
ClinicalTrials.gov Identifier:
|
NCT04449874
|
This study is currently active and recruiting participants
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Ontario
The Ottawa Hospital
Princess Margaret Cancer Centre, Toronto
Quebec
Jewish General Hospital, Montreal
|
ClinicalTrials.gov Identifier:
|
NCT05067283
|
This study is currently recruiting participants.
This is a study evaluating the efficacy, safety, and pharmacokinetics of MK-1084 in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.
Ontario
Hamilton Health Sciences, Juravinski Cancer Centre
Princess Margaret Cancer Centre, Toronto
|
ClinicalTrials.gov Identifier:
|
NCT04613596
|
This study is currently recruiting participants.
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.
The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab plus chemotherapy in patients with unresectable, locally advanced or metastatic nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS <50% and who are candidates for first line treatment.
British Columbia
Vancouver
Ontario
Ottawa
Toronto
| ClinicalTrials.gov Identifier: |
NCT04956640 |
This study is currently recruiting participants.
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years
Alberta
Cross Cancer Institute, Edmonton
Contact 855-569-6305
Ontario
Princess Margaret Hospital, Toronto
Contact 855-569-6305
| ClinicalTrials.gov Identifier: |
NCT04303780 |
This study is currently recruiting participants.
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
Ontario
Hamilton
Ottawa
London
Toronto
| ClinicalTrials.gov Identifier: |
NCT04185883 |
This study is currently recruiting participants.
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors
Quebec
Laval
MET
| ClinicalTrials.gov Identifier: |
NCT05488314 |
This study is currently recruiting participants.
The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD[s]) of the amivantamab and capmatinib combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection), and to evaluate the antitumor effect of the amivantamab and capmatinib combination therapy in mesenchymal-epithelial transition (MET) exon 14 skipping mutation and MET amplified NSCLC, when administered at the selected RP2CD(s) in Phase 2 (expansion).
Ontario
The Ottawa Hospital Research Institute, Ottawa
University Health Network (UHN) Princess Margaret Cancer Centre, Toronto
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
|
ClinicalTrials.gov Identifier:
|
NCT04084717
|
This study is currently active and recruiting participants
This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer.
Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.
Ontario
Princes Margaret Hospital, Toronto
| ClinicalTrials.gov Identifier: |
NCT03175224 |
This study is currently active and recruiting participants
The primary Phase 1 purpose of this study was to assess overall safety, tolerability and recommended Phase 2 dose (RP2D) of APL-101.
The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations; individuals with cancers associated with c-Met amplifications; individuals with cancers associated with c-Met fusion
Alberta
Edmonton
Manitoba
Winnipeg
Ontario
Toronto
Quebec
| ClinicalTrials.gov Identifier: |
NCT04931654 |
This study is currently active and recruiting participants
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib
Alberta
Calgary
Edmonton
Ontario
Newmarket
North York
Toronto
| ClinicalTrials.gov Identifier: |
NCT03539536 |
This study is currently active but not recruiting participants
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
Alberta
Cross Cancer Institute, Edmonton
Ontario
Ottawa Hospital, Ottawa
Princess Margaret Hospital, Toronto
Quebec
CISSS de la Monteregie, Greenfield Park
| ClinicalTrials.gov Identifier: |
NCT02609776 |
This study is active, but not recruiting participants
The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).
British Columbia
Vancouver
Ontario
University Health Network, Toronto
NRG1
| ClinicalTrials.gov Identifier: |
NCT02912949 |
This study is currently active and recruiting participants
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Ontario
Toronto
NTRK
|
ClinicalTrials.gov Identifier:
|
NCT03093116
|
This study is currently active and recruiting participants
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.
Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Alberta
Edmonton
British Colombia
Vancouver
Ontario
Brampton
Ottawa
Toronto
RET
| ClinicalTrials.gov Identifier |
NCT04819100 |
This study is currently recruiting.
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.
Ontario
Princess Margaret Hospital, Toronto
Principal Investigator: Penelope Bradbury
|
ClinicalTrials.gov Identifier:
|
NCT04194944
|
This study is active but not currently recruiting.
The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
Alberta
Cross Cancer Institute
Ontario
Princess Margaret Hospital, Toronto
ROS1
|
ClinicalTrials.gov Identifier:
|
NCT03093116
|
This study is currently active and recruiting participants
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.
Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Alberta
Edmonton
British Colombia
Vancouver
Ontario
Brampton
Ottawa
Toronto
|
ClinicalTrials.gov Identifier:
|
NCT06140836
|
This study is currently active and recruiting participants
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
Ontario
Toronto, Princess Margaret Cancer Centre
Contact: Geoffrey Liu, Site 0002, 416-824-1217
Quebec
Trois-Rivières, Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec
Contact: Jean Sebastien Aucoin, Site 0123, 819-697-3333
| ClinicalTrials.gov Identifier: |
NCT05118789 |
This study is currently recruiting participants.
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors.
Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumors.
Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-520 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-520 in patients with advanced ROS1-positive NSCLC and other solid tumors.
Alberta
Cross Cancer Institute, Edmonton
Principal Investigator: Quincy Chu, MD
Ontario
Princess Margaret Cancer Research, Toronto
Principal Investigator: Geoffrey Liu, MD
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II)
|
ClinicalTrials.gov Identifier:
|
NCT04919811
|
This study is currently recruiting participants.
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Ontario
Princess Margaret Cancer Centre, Toronto
Quebec
McGill University Health Centre Research Institute, Montréal
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
|
ClinicalTrials.gov Identifier:
|
NCT04084717
|
This study is currently active and recruiting participants
This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer.
Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.
Ontario
Princes Margaret Hospital, Toronto
| ClinicalTrials.gov Identifier: |
NCT04919811 |
This study is currently recruiting participants.
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Ontario
Princess Margaret Cancer Centre, Toronto
Quebec
McGill University Health Centre Research Institute, Montréal